The average selling price for VERCISE GEVIA in Norway dropped in 2022, according to GlobalData. The average selling price, the complete price range of high and low prices and a 3-year forecast for the VERCISE GEVIA device in Norway can be viewed in GlobalData’s micro pricing report. Buy the report here.
The VERCISE GEVIA is sold by Boston Scientific in the Deep Brain Stimulators market. A Deep Brain Stimulator (DBS) is a device that is comprised of a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation through surgically-implanted electrodes to specific targets in the brain. DBSs are commonly used to treat movement disorders as well as neuropsychiatric disorders.
Factors contributing to the list price of a medical device include but are not limited to therapy area, complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. Moreover, final selling prices vary geographically and by facility type. These prices are further subject to discounts, as well as purchasing and distribution agreements.
For a complete picture of Boston Scientific’ Deep Brain Stimulators device pricing in Norway, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.